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The availability of monoclonal antibodies (mAb) 1 specific for human surface 
membrane antigens (1) has resulted in rapid progress toward elucidation of the 
nature  of the molecules involved in cytolytic T  lymphocyte (CTL)-target  cell 
interactions. Since target cell lysis requires close contact between CTL and target 
cells, a  general approach  to this question has been  the identification of mAb 
directed against CTL surface structures that inhibit cytolysis when added (in the 
absence of complement) to CTL-target  cell  mixtures (2).  For example,  work 
from several groups showed that mAb against TS/Leu-2 and T3/Leu-4 surface 
molecules inhibit the cytolytic activity of T cell populations activated in allogeneic 
mixed  lymphocyte culture  (MLC)  (3-9).  Recently,  studies  using CTL  clones 
suggested that anti-T3 mAb inhibits the activity of all CTL irrespective of their 
T8/T4 phenotype, whereas anti-T8 and anti-T4 mAb selectively inhibit cytolysis 
mediated by T8 ÷ and T4 + CTL, respectively (10). In the mouse, it has been well 
documented that mAb against Lyt-2/3,  the murine homologue of T8 antigen, 
can inhibit CTL-mediated iysis (11). However, the degree of inhibition obtained 
with anti-Lyt-2/3  mAb appears to be dependent on the source of CTL  used. 
For example, the CTL activity of primary allogeneic MLC populations was found 
to be readily inhibited by anti-Lyt-2/3 mAb, whereas alloreactive CTL popula- 
tions generated in vivo or in secondary (after priming in vitro) MLC were more 
difficult to inhibit under the same experimental conditions. The cellular basis 
for this difference has been clarified by the analysis of CTL clones derived from 
these populations. Thus,  most (but not all) CTL clones derived from primary 
MLC were strongly inhibited by anti-Lyt-2/3 mAb, whereas, the activity of most 
(but not all) CTL clones derived from in vivo primed precursors was resistant to 
inhibition by these antibodies (12). These studies strongly suggest that CTL are 
heterogeneous in their requirement for Lyt-2/3 molecules in cytolytic activity. 
Recently, Malissen et al. (8) reported that B9.4 mAb (which appears to react 
with surface  molecules bearing the  Leu-2a/b  and T8  antigenic determinants) 
' Abbreviations used in this paper: CTL, cytolytic T  lymphocyte; FACS, fluorescence-activated cell 
sorter;  FCS, fetal calf serum; FITC, fluorescein isothocyanate; mAb, monoclonal antibodies; MLC, 
mixed lymphocyte culture; PBS, phosphate-buffered  saline; PHA, phytohemagglutinin; TCGF, T 
cell growth factor. 
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(13), inhibited only a minority of human CTL clones derived from an ailoimmune 
donor. Since this finding was reminiscent of the above-mentioned results in the 
mouse, we thought it of interest to determine whether there is heterogeneity in 
the  involvement of molecules such  as  T8,  T4,  and  T3  in  the  lytic activity of 
human CTE. Therefore, a  large number of primary MLC-derived CTL clones 
were examined for their susceptibility to inhibition by mAb directed against T8, 
T4, and T3 molecules respectively. In agreement with the results obtained with 
murine  Lyt-2  ÷  CTL,  it  will  be  shown  that,  although  the  majority of primary 
MLC-derived CTL clones expressing T8 antigen  are inhibited by B9.4.  mAb, 
~15% are unaffected by this antibody. Moreover, a similar heterogeneity in the 
susceptibility to inhibition by the corresponding mAb has been documented for 
CTL clones expressing T4 molecules. Furthermore, evidence will be presented 
that the lytic activity of a  significant proportion of CTL clones is unaffected by 
anti-T3  mAb.  Finally,  modulation  experiments  on  CTL  clones  indicate  that 
removal of surface T3 molecules is not always accompanied by the loss of specific 
cytolytic activity, thus  suggesting  that receptor structures on the  CTL surface 
are not always functionally associated with T3 molecules. 
Materials and Methods 
Generation of Alloimmune  CTL.  Cytolytic T  cells were generated in vitro in unidirec- 
tional mixed lymphocyte cultures (MLC) as previously described (14). Briefly 106 periph- 
eral blood T  lymphocytes from normal donors were cultures with  106 irradiated (5,000 
rads) allogeneic spleen cells for 7 d in macrowells (final volume 1 ml). The culture medium 
was RPMI  1640 containing 10% heat-inactivated fetal calf serum (FCS) (Gibco Labora- 
tories, Grand  Island,  NY).  Human spleens were removed for technical reasons during 
abdominal surgery. Mononuclear cell suspensions derived from spleens were frozen and 
subsequently thawed as needed (15). 
mAb.  The B9.4 mAb (directed to T8 surface antigen) was kindly provided by Dr. C. 
Mawas  and  B.  Malissen  (Centre  d'Immunologie  INSERM-CNRS,  Marseille-Luminy, 
France),  the  4F2  mAb  was  a  gift of Dr.  A.  S.  Fauci  (National  Institutes  of Health, 
Bethesda,  MD).  OKT4 and OKT3 mAb were purchased from Ortho-Pharmaceuticais 
(Raritan, N  J). 
Cytolytic Assay.  The techniques used have been described in previous reports (16, 17). 
Briefly, various numbers  of alloimmune primary MLC  T  cells  or T  cell clones were 
incubated for 4 h with ~Cr-labeled target cells (5 ×  103/well) in a final volume of 200 #1 
in "V'-bottomed microwells (Greiner Nurtinger, Federal Republic of Germany). Target 
cells were PHA-activated spleen-derived lymphoblasts bearing the sensitizing alloantigens 
or K 562 cells (in some control experiments). In the inhibition experiments, before the 
addition of target cells,  MLC T  cells or T  cell clones were preincubated for 30 min at 
20°C with various doses of B9.4, OKT4, or OKT3 mAb. B9.4 mAb was added at a final 
concentration of 1 ~g/microwell (5 ~g/ml) unless otherwise specified. OKT4 or OKT3 
mAb were added in aliquots of 10 ~1 of the standard solution to each 200-ttl microweil, 
unless otherwise specified. When necessary, MLC ceils after preincubation with mAb were 
washed three times to remove the antibody. Microplates were centrifuged at 100 g for 5 
rain and then incubated at 37°C.  After 4 h, microplates were centrifuged again (200 g 
for 5 min) and 100 #1 supernatant was removed and counted for 1 min in a scintillation 
51J  counter. Percent specific  Cr release was calculated as described previously (18), whereas 
spontaneous release was determined in the absence of effector cells and maximal release 
was determined in the presence of 1 N hydrochloric acid. 
Cloning  of MLC Cells.  This technique has  been described in  previous reports (19). 
Briefly, primary MLC T  cells  were submitted to vigorous vortex mixing (to dissociate 
possible cell clumps) and then seeded under limiting conditions (0.3 ceils/well) in round- MORETTA  ET AL.  923 
bottomed microwells containing 105 irradiated stimulator spleen cells.  The culture me- 
dium was RPMI 1640 containing 10% FCS and 40% supernate from phytohemagglutinin 
(PHA)-stimulated human spleen cell cultures (as source of T  cell growth factor (TCGF) 
(20). 
Screening of Proliferating and/or Cytolytic Clones.  Clones derived from primary MLC T 
cells  were  identified microscopically after  12-20  d  as  previously described (19).  Cell 
aliquots (usually 50 ttl of the cell suspension) from proliferating microcultures were tested 
for cytolytic activity against SlCr-labeled specific target cells.  In inhibition experiments, 
cells were preincubated with mAb for 30 min before the addition of the target cells. 
Immunofluorescence Staining and Fluorescence-activated Cell Sorter (FACS) Sorting.  The 
techniques used have been previously described (21). Briefly, samples of 2 ×  106 MLC T 
cells  in  100 ~tl RPMI  1640 medium  were incubated with  B9.4 or OKT4 monoclonal 
antibodies for 30 min at 4°C. After two washings,  the cells were resuspended in 200 ~tl of 
medium containing fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG. 
Control samples were incubated with the FITC-coupled reagent only. Before sorting cells, 
the sample tubing of the FACS was flushed sequentially with detergent, sterile distilled 
water,  and 96%  ethanol.  Then, the tubing was  rinsed for 30  rain  with  a  solution of 
gentamycin  (50  ttg/ml)  in  phosphate-buffered saline  (PBS).  Because the  fluorescence 
profiles of cells stained with B9.4 or OKT4 mAb were clearly biphasic (see Fig.  1), <5% 
of all cells had to be discarded because their fluorescence intensity coincided with the 
inflection point of the curve. Sorted cells were collected in sterile plastic tubes whose 
inside surfaces had been coated with sterile FCS. Once collected, cells were immediately 
diluted in culture medium. 
Flow Cytofluorometric Analysis of TS, T4, and T3 Antigen Expression in Cloned CTL.  The 
techniques used have been described in detail elsewhere (17). Briefly, aliquots of 10  s cells 
from a  number of CTL clones were stained with monoclonal either B9.4,  OKT4,  or 
OKT3 antibodies followed by fiuorosceinated goat anti-mouse Ig. Control aliquots were 
stained with the  fluorescent reagent alone.  All samples were then analyzed on a  flow 
cytometer (FACS II; Becton Dickinson, Mountain View, CA) gated to exclude nonviable 
cells.  Further  details  of the  FACS  analysis  are  described elsewhere (21).  Results  are 
expressed as  arbitrarily  normalized  fluorescence histograms  i.e.,  number  of cells  vs. 
fluorescence intensity. 
Modulation of Surface T3 Antigen by OKT3 mAb.  Cells from clone A-11  or A-2, at 2 X 
10n/ml, were incubated in the presence or absence of saturating amounts of OKT3 mAb. 
After 24 h the ceils were washed twice and analyzed for expression of T3 antigen (on a 
FACS II) and for specific CTL activity. 
Results 
Inhibitory  Effect  of B9.4  mAb on  the  Lytic Activity  of Primary MLC-derived  CTL 
Populations.  In a  first series of experiments, primary MLC-derived CTL popu- 
lations were  tested  for specific cytolytic activity in  the presence or absence  of 
graded amounts of anti-T8 B9.4 mAb. As shown in Fig. 1, addition of B9.4 mAb 
resulted in a  dose-dependent inhibition of cytolytic activity. It should be noted 
that  the  maximal  level  of inhibition  never  exceeded  85%,  even  in  antibody 
excess. The inhibitory effect was found to be reversible since the lytic activity of 
MLC  cells  that  had  been  pretreated  with  a  saturating  dose  of antibody  and 
washed before the cytolytic assay was similar to that of untreated MLC cells (data 
not shown).  Under  the same  experimental conditions,  4F2  mAb,  which  reacts 
with  a  surface  structure  expressed  by MLC-derived  CTL  and  belongs  to  the 
same (3~ 2a) subclass as B9.4 mAb (22), was not inhibitory, even when added in 
large excess (Fig.  1). 
Clonal  Analysis  of CTL Inhibition  by B9.4  mAb.  To investigate the  inhibitory 
effect of B9.4 mAb at the clonal level, we derived a large number of CTL clones 924  CLONAL  HETEROGENEITY 
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FIGURr  1.  Inhibitory effect of B9.4 mAb on the CTL activity exhibited by 7 d primary MLC 
2 ×  t0  MLC cells were preincubated for 30 rain at 20°C with increasing  cells. Aliquots of  5 
doses of B9.4 (O) or 4F2 (O) mAb. 5  ×  10 s ~lCr-labeled PHA-activated blast cells bearing the 
sensitizing alloantigens were then added and specific cytolytic activity measured 4 h later. The 
results are expressed as percent specific SlCr release (panel A) and as percent inhibition (panel 
B). 
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FIGURE  2.  Effect of B9.4 mAb on the specific cytolytic activity of CTL clones derived from 
7-d primary MLC cells.  Aliquots of CTL clones were incubated for 30 rain at 20°C in the 
presence or absence of 1 #g of B9.4 mAb. Cytolytic activity was then determined using n~Cr- 
labeled  PHA  activated  lymphocytes bearing 5tthe stimulating alloantigens.. The  dotted  hne" 
represents 3 SD above the mean spontaneous  Cr release. Each point represents the control 
vs.  the  "inhibited" cytotoxicity  values of a  single clone.  Clones resistant to  B9.4-mediated 
inhibition would thus fall close to the 45 ° line. 
from MLC populations  by limiting dilution  or micromanipulation  of single cells. 
As described  previously  (17),  the  cloning  efficiency in  the  microculture  system 
we are using is 50-80%.  After  ] 4-18  d  of culture,  clones were tested for specific 
CTL  activity  in  the  presence  or  absence  of  1  #g  B9.4  mAb.  The  results  of a 
representative  experiments  involving  52  CTL  clones are shown  in Fig.  2.  It can MORETTA  ET  AL.  925 
w 
W 
.Jw  <  100  :elllt~ 
G  :*.  * 
-  ,e;  • 
u_  ~  ,i °  , 
"  ~so  q  •  (,1 o  w 0  • 
(o 
Z 
U  •1 
Iz 
w  0 
L  !  ! 
0  50  100 
PERCENT  SPECIFIC  S1Cr RELEASE 
(B9.4  mAb) 
FIGURE 3.  Effect  of B9.4 mAb on the specific cytolytic  activity  of T8  ÷ CTL clones derived 
from the T8  ÷  cell fraction of 7-d primary MLC populations. The experimental design is similar 
to that detailed in the legend to Fig. 2. Note that 5 of the 23 T8  ÷ CTL clones analyzed were 
not inhibited by addition of B9.4 mAb. 
be seen that CTL clones were heterogeneous in their susceptibility to inhibition 
of cytolysis by B9.4 mAb. While the majority of clones was either completely or 
strongly inhibited, seven clones were either unaffected or minimally inhibited. 
The lack of inhibition by B9.4 mAb could possibly be explained by the lack of 
corresponding antigen on the cell surface of these clones. In an attempt to clarify 
this point,  we repeated  this experiment  using clones derived  form  MLC T8 ÷ 
populations that had been positively selected by FACS sorting of B9.4-stained 
cells. The CTL clones thus obtained were analyzed for susceptibility to inhibition 
by B9.4 mAb. The results of a representative experiment are shown in Fig. 3. It 
can be  seen  that even  within CTL clones selected on  the basis of T8  antigen 
expression,  a  considerable  degree  of heterogeneity was  observed.  Of the  23 
clones tested, 5 were unaffected in their activity by B9.4 mAb. In three different 
experiments,  13-22;%  of T8 ÷ CTL clones belonged to the latter category. To 
further document this finding seven uninhibited clones were selected, expanded, 
and re-tested for lytic activity in the presence of increasing antibody concentra- 
tions. None of the seven clones showed any significant (>5%) inhibition even at 
doses of B9.4 as high as 5 #g. In a control experiment, 15 T8- CTL clones were 
selected  and  analyzed for  their  susceptibility  to  inhibition  by  B9.4  mAb.  As 
expected, none of them was affected even in the presence of an excess (5 #g) of 
B9.4 mAb (data not shown). 
Quantitative Analysis of T8 Antigen Expression  on  T8  + CTL Clones.  The differ- 
ence in susceptibility of T8 + CTL clones to inhibition by B9.4  mAb could be 
explained by a  difference in  the amount of T8  antigen expressed  on  the cell 
surface. This possibility was examined by assessing the level of T8  antigen on 
several  inhibited and uninhibited clones.  To  this end, cell aliquots from each 
clone were incubated first with B9.4 mAb and then with a  goat fluoresceinated 
antibody anti-mouse immunoglobulin, and then analyzed by flow microfluoro- 
metry. In parallel, the lytic activity of each clone was tested in the presence or 926  CLONAL HETEROGENEITY 
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FIGURE 4.  Flow cytofluorometric analysis  of T8 antigen expression of T8  + CTL  clones 
susceptible or resistant to inhibition by B9.4 mAb. Aliquots of six representative clones were 
incubated with B9.4 mAb for 30 min at 4°C, washed and stained with fluoresceinated goat 
anti-mouse Ig. Samples were analyzed in a FACS II. Note that the lytic activity of clones 4, 
11, and 22 was completely inhibited by B9.4 mAb, whereas clones 16,  17, and 39 were 
unaffected by the antibody. 
absence  of B0.4  mAb.  In  Fig.  4  are  shown  the  fluorescence  profiles  of six 
representative CTL clones: the lytic activity of three of them (clones 4, 22, and 
11) was completely blocked by B9.4  mAb, whereas the other three (clones  16, 
39, and  17) were insensitive to the antibody. Although some quantitative varia- 
tions  in  the  expression  of T8  antigen  were  observed  among these  clones,  no 
correlation could be found between the amount of T8 antigen, the magnitude 
of cytolytic activity and the degree of inhibition of cytolysis by B9.4 mAb. 
Clonal Analysis of CTL Inhibition by Anti-T4 mAb.  A  similar approach was used 
to examine the inhibitory effect of anti-T4  mAb at the clonal  level.  T4 + cells 
were isolated from MLC populations by sorting using the FACS, and cloned by 
limiting dilution. Out of 212  clones obtained under these conditions,  14 were 
found to exhibit specific cytolytic activity against the stimulating allogeneic cells. 
These CTL clones were tested for expression of T4 antigen by indirect immu- 
nofluorescence  on  the  FACS.  As  expected,  all  of them  displayed  the  T4 + 
phenotype (data not shown). Analysis of the susceptibility of these T4 + clones to 
inhibition  by anti-T4  mAb  was performed  as  described  above  for  T8 + CTL 
clones. As shown in Fig. 5, there was a striking heterogeneity in the susceptibility 
of these T4 + CTL clones to inhibition of cytolysis by anti-T4 mAb. Indeed, only 
6 of the 14 clones tested were affected by anti-T4 mAb. Further analysis indicated 
that seven of the eight uninhibited CTL clones were not affected even at a dose 
of anti-T4  mAb  10-fold higher than that sufficient for complete inhibition of 
susceptible clones. Moreover, no correlation was observed between the amount MORETTA  ET  AL.  927 
<  100 
Ill 
.J 
m 
~.~  so 
o 
w 
L 
W 
I- 
Z 
IAI 
w  0  o  I 
I 
'o  o  5  lOO 
PERCENT  8PECiFICSIcr  RELEASE 
(OKT4  mAb) 
FIGtSRE 5.  Efl-ect of OKT4 mAb on the specific cytolytic activity of T4  + CTL clones derived 
from the T4  + cell fraction of 7-d primary MLC populations. The experimental design is similar 
to that described in the legend to Fig. 2. Note that 8 of the 14 T4  + CTL clones tested were 
not (or minimally) inhibited by addition of OKT4 mAb. 
of T4 antigen expressed on the cell surface of a given clone and its susceptibility 
to inhibition  by anti-T4 mAb (data not shown). 
Clonal Analysis of CTL Inhibition by Anti-T3 mAb.  It has been recently suggested 
that  the T3 surface molecule (which is expressed on CTL irrespective of their 
subset distribution) is closely linked to the T  cell receptor structure (23, 24). In 
view of the heterogeneity of inhibition observed with anti-T8 and anti-T4 mAb, 
it  was of considerable  interest  to determine  whether all  CTL  clones could be 
inhibited  by anti-T3  mAb.  To  this  end,  the  same  sets of T8 + and  T4  + CTL 
clones that had been tested above were analyzed for expression of T3 antigen as 
well as susceptibility to inhibition  by anti-T3  mAb. In accordance with previous 
reports, all the clones analyzed expressed the T3 antigen  as assessed by micro- 
fluorometry (data not shown).  The inhibitory activity of anti-T3  mAb on T8 + 
CTL clones is shown in Fig. 6. It can be seen that only 15 of the 23 CTL clones 
tested were clearly inhibited by anti-T3  mAb. Moreover, the number of clones 
that were not inhibited by anti-T3 mAb exceeded that of clones not inhibited by 
B9.4 mAb (eight vs. five). It is of interest that four of the five clones unaffected 
by B9.4 mAb were also resistant to anti-T3  mAb. Moreover, three clones were 
only inhibited by B9.4 mAb, whereas clones that were only inhibited by anti-T3 
were relatively rare (1  out of 23 in  the experiment reported in Fig. 6).  Clones 
resistant to the standard amount of anti-T3 mAb were still  unaffected by doses 
10-fold higher of mAb (data not shown). The inhibitory effect of anti-T3  mAb 
on 14 T4 + CTL clones is shown in Fig. 7. Again, both inhibited and not inhibited 
clones were clearly observed. While several clones were found to be resistant to 
both anti-T3  and  anti-T4  mAbs, eight clones appeared  to be sensitive only to 
anti-T3  mediated inhibition.  It is noteworthy that  the proportions of T4 + and 
T8 + CTL  clones inhibited  by anti-T3  mAb were comparable  (72%  and  65%, 
respectively). 
Differential Effect ofT3 Modulation  on the Lytic Activity of CTL Clones.  It is well 
documented that anti-T3 mAb can induce modulation of T3 molecules (10, 26). 928  CLONAL  HETEROGENEITY 
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FI6uRE  6.  Effect of OKT3  mAb on the specific cytolytic activity of T8 ÷ CTL  clones. The 
set of clones analyzed is the same as that displayed in Fig. 3.  Note that 8  of the 23 T8 + CTL 
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FIGURE  7.  Effect of the  OKT3  mAb on  the specific cytolytic activity  of T4 + CTL  clones 
derived  from  primary  MLC  populations.  The  set  of  clones  analyzed  is  the  same  as  that 
displayed in Fig. 5. Note that 8 of the 14 clones were totally inhibited by OKT3 mAb, 3 were 
partially  inhibited, and  3  were  unaffected.  The  8  clones marked  with an open  triangle are 
those resistant to OKT4  inhibition (see Fig. 5). 
Moreover, studies using CTL clones showed that  modulation  of T3  molecules 
was  accompanied  selectively  by a  loss  of surface  structures  defined  by anti- 
clonotypic mAb, and  resulted  in a  marked  inhibition  of cytolytic activity (24). 
Given the fact that the clones used in these studies were susceptible to inhibition 
by anti-T3  mAb present  during  the  cytolytic assay,  we therefore  investigated 
whether a  similar effect could be observed with CTL clones that were resistant 
to inhibition by anti-T3 mAb. To this end, we selected two CTL clones, namely 
the clone A-11  which was resistant  and  the clone A-2 which,  on the contrary, 
was highly  susceptible to  inhibition  by anti-T3  mAb  (Fig.  8).  Both  clones ex- 
pressed the  T3 +,  T8 ÷, T4- surface phenotype and  were unable to lyse K  562 
target cells. Incubation  with anti-T3  mAb during  24 h at 37°C resulted in  the MORETTA  ET  AL.  929 
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FIGURE 9.  Modulation of T3 surface antigen by anti-T3 treatment of clones A-11 and A-2. 
Cells were incubated with saturating amounts of OKT3 mAb for 24 h at 37 °C. After extensive 
washing, the presence of OKT3 on the cell surface was assessed by indirect immunofluores- 
cence using the FAGS. The fluroescent histogram of modulated ceils is compared to a control 
histogram  obtained  with  unmodulated  cells.  The  dotted  line  represents  the  background 
fluorescence given by the goat anti-mouse fluoresceinated Ig. 
loss of T3 molecules on the surface of both clones (Fig.  9). However, when the 
modulated clones were tested in parallel for specific CTL activity, clone A-2 was 
found to exhibit little activity,  whereas the lytic activity of clone A-11  was only 
minimally affected (<10%  inhibition) by T3 modulation (Fig.  10). 
Discussion 
In the present study, the involvement of surface structures recognized by the 
B9.4, OKT4, and OKT3 mAb in the activity of human CTL was analyzed at the 
clonal level. The results clearly demonstrate that CTL are clonally heterogeneous 
in their susceptibility to inhibition by all three mAb. Since the expression of T8 
and T4  molecules on the CTL surface is mutually exclusive (10),  it is obvious 930  CLONAL HETEROGENEITY 
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the absence of saturating amounts ofOKT3 mAb for 24 h at 37°C. After extensive washing, 
graded numbers of cells were mixed with 5 x  l0  s SlCr-labeled PHA-activated  lymphoblasts 
bearing the sensitizing  alloantigens,  and cytolytic  activity  was determined after 4 h. 
that the lack of inhibitory activity of B9.4 or OKT4 mAb on some CTL clones 
could simply be  explained  by the  lack of the  corresponding  structure  on  the 
effector cells.  However,  heterogeneity of inhibition was observed also  among 
CTL clones bearing the corresponding molecules. Thus, although the majority 
of primary  MLC-derived  CTL  clones  expressing  T8  molecules  were  either 
completely or strongly inhibited by B9.4 mAb, ~15%  were inhibited minimally 
or unaffected. Interestingly, the susceptibility (or the lack thereof) of these clones 
to  inhibition  by B9.4  mAb  did not correlate  with  the  amount of T8  antigen 
expressed  on  the  cell  surface.  Similarly, among T4 + CTL clones,  some  were 
completely inhibited by OKT4  mAb,  whereas others were unaffected even by 
an excess of antibody. 
In the clonal analysis performed by Meuer et al. (3) all the T8 + CTL clones 
examined were found to be susceptible to inhibition by anti-T8 mAb. In contrast, 
Malissen  et  al.  (8)  reported  that  only  a  minority  of T8 +  CTL  clones  were 
susceptible to inhibition by B9.4 mAb. These apparently conflicting findings can 
be  reconciled  on  the  basis  of the  data  reported  here,  as  well  as  the  results 
obtained in the mouse concerning the role  of the  Lyt-2/3 antigen complex in 
CTL activity. As shown by MacDonald et al. (12), there is considerable hetero- 
geneity  in  the  susceptibility  of murine  Lyt-2/3  +  CTL  to  inhibition  by  mAb 
directed against Lyt-2 or Lyt-3 antigenic determinants. Moreover, the proportion 
of CTL  clones  that  are  unaffected by  anti-Lyt-2/3  antibodies  appears  to  be 
dependent on the source of CTL. In the study by MacDonald et al. (12), <20% 
of CTL clones derived  from  MLC populations established with unprimed re- 
sponder lymphocytes were not inhibited by anti-Lyt-2 mAb as compared to 60- 
75%  of CTL  clones  obtained  from  in  vivo  immunized  populations.  In  this 
context, it is noteworthy that the human CTL clones studied by Malissen et al. 
(8), were derived from an allosensitized individual. As shown here, only a small 
fraction of human T8 ÷ CTL clones derived from primary MLC populations was 
unaffected by B9.4 mAb. It is therefore likely that the results of Meuer eta]. (3), MORETTA  ET  AL.  931 
who  used  T8 ÷ CTL  clones  derived from primary  MLC  populations,  can  be 
explained by the limited number of CTL clones examined. Taken together, all 
these results point to a striking functional similarity between the mouse Lyt-2/3 
and the human T8  molecules, since in  both  instances, the resistance of CTL 
clones  bearing  these  antigens  to  inhibition  by  the  corresponding antibodies 
appears to correlate quantitatively (but not absolutely) with in vivo priming. 
While Meuer et al. reported that T4 ÷ CTL clones were inhibited by anti-T4 
mAb, opposite results were obtained by Spitz et al. (7). From the work presented 
here, it is evident that, as in the case of T8 molecules, the requirement for T4 
molecules in the cytolytic activity of T4  ÷ CTL exhibits clonal heterogeneity. It 
has been suggested that T8 and T4 molecules can act as associative recognition 
structures by virtue of their binding to the constant region of MHC class  I or 
class II molecules, respectively (26). Alternatively, as proposed by MacDonald et 
al.  (27)  to  explain  the  clonal  heterogeneity in  the  requirement for  Lyt-2/3 
molecules in the iytic activity of murine CTL, it can be speculated that the role 
of T8  and T4  molecules is  to  stabilize  the binding  of CTL  receptors to  the 
corresponding antigens. In either case, one would expect that CTL clones with 
high affinity receptors do not require additional surface molecules to mediate 
their function and therefore are not  inhibited by anti-T8  or -T4  antibodies. 
Comparative studies using CTL clones derived from both unprimed and primed 
lymphoid cell populations might help to clarify this issue. Perhaps more impor- 
tantly,  the  present  study  indicates  that  heterogeneity may  also  exist  in  the 
requirement of T3 molecules for CTL activity. Several lines of evidence suggest 
that T3 molecules are closely associated with T  cell antigen receptors (24,  25, 
28,  29).  Firstly,  as already mentioned, the determinants recognized by  mAb 
directed against clonotypic structures of CTL clones were found to be absent 
from the cell surface after modulation  of T3  molecules by anti-T3  mAb.  In 
addition,  modulation of T3  molecules resulted in a  marked reduction of the 
activity of such clones. Secondly, it has been shown that soluble anti-T3  mAb 
can  inhibit  the  proliferative  response  of T  cell  clones  to  insolubilized  anti- 
clonotypic mAb. Finally, it appears that detectable amounts of molecules bearing 
clonotypic determinants can be co-precipitated by anti-T3  mAb.  It should be 
emphasized, however, that the number of CTL clones used in all these studies 
has been very limited. Indeed, our work indicates that about two-thirds of the 
CTL clones derived from primary MLC populations required T3 molecules for 
target cell lysis.  In contrast, the remaining clones, irrespective of their T4/T8 
phenotype, did not appear to be dependent upon T3 molecules as indicated by 
the lack of inhibitory activity of anti-T3  mAb. In support of this contention is 
the demonstration that the cytolytic activity ofa CTL clone resistant to inhibition 
by anti-T3  mAb was unaffected by antibody-induced modulation of T3  mole- 
cules.  This  finding  strongly  suggest  that  T3  molecules  and  the  clonotypic 
structures, which are thought to act as antigen receptors, are not always physically 
and  functionally linked  on  the  CTL  surface.  Further  work  using  antibodies 
against clonotypic structures of CTL clones that are independent of T3 molecules 
is needed to ascertain directly this point. Moreover, it remains to be determined 
whether  the  proportion  of T3-independent  CTL  is  increased  after  in  vivo 
priming. 932  CLONAL  HETEROGENEITY 
Summary 
In an attempt to define the requirement of T8, T4, and T3 surface molecules 
in  functional  interactions  occurring  between  human  cytolytic T  lymphocytes 
(CTL) and specific target cells, we have analyzed a large number of CTL clones 
derived from primary mixed lymphocyte culture (MLC) T  cell populations for 
their susceptibility to inhibition by monoclonai antibodies (mAb) directed against 
these surface antigens. In most experiments, MLC T  cells were stained with B9.4 
(anti-T8)  or OKT4  (anti-T4)  mAb,  separated  into  positive and  negative  cells 
using  a  fluorescence-activated  cell  sorter  (FACS)  and  cloned  under  limiting 
conditions.  While  the  lytic  activity  of the  majority  of T8 +  CTL  clones  was 
inhibited  by  B9.4  mAb,  ~15%  of these  clones  were  unaffected  even  in  the 
presence  of excess antibody.  Flow cytofluorometric analysis  of T8  antigen  in 
individual clones did not show any correlation between the amount of T8 antigen 
expressed,  the  magnitude  of cytolytic activity  and  the  susceptibility  (or  lack 
thereo{) to inhibition by B9.4 mAb. Of the 16 T4 + CTL clones analyzed, 7 were 
resistant  to inhibition  by OKT4  mAb  even at  doses  10-fold higher  than  that 
sufficient for complete inhibition of susceptible clones. Again, no correlation was 
found between the amount  of T4  antigen  expressed and  the  susceptibility to 
inhibition by the corresponding antibody. 
The  same  sets  of T8 +  and  T4 +  CTL  clones  were  also  analyzed  for  their 
susceptibility to inhibition by OKT3 mAb. Although all of the clones expressed 
the  T3  surface  antigen,  only  15/23  T8 +  clones  and  9/14  T4 +  clones  were 
inhibited by anti-T3  mAb. To further  document this clonal heterogeneity, we 
selected two T3 + T4- T8 + CTL clones that had no concomitant NK-like activity. 
One clone  was resistant  to inhibition  by OKT3  mAb,  whereas  the  other  was 
highly susceptible.  Incubation  with  OKT3  mAb resulted  in modulation  of the 
T3  molecules  in  both  clones.  Following  modulation,  however,  the  cytolytic 
activity of the resistant $:lones  was unaffected, whereas the lytic activity of the 
susceptible  clone  was abrogated.  These  results  thus  indicate  extensive  clonal 
heterogeneity in the requirement for T3, T4, and T8 molecules in CTL function. 
Moreover, it appears that T3 molecules are not always physically and functionally 
linked to CTL receptor structures. 
Received  for publication 30 November 1983. 
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